Glycine reuptake inhibitors in the treatment of negative symptoms of schizophrenia

Klinik Psikofarmakoloji Bulteni

Volumn 24, Issue 3, 2014, Pages 195-200

  Thomas, Reji ^a   Baker, Glen ^a   Dursun, Serdar ^a   Todd, Kathryn ^a   Dhami, Kamaldeep ^a   Chue, James ^a   Chue, Pierre ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bitopertin; Glycine reuptake inhibitors; Sarcosine; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; BENZOIC ACID; BITOPERTIN; CLOZAPINE; GLYCINE REUPTAKE INHIBITOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITROPRUSSIDE SODIUM; OLANZAPINE; PLACEBO; PROTEIN INHIBITOR; SARCOSINE; UNCLASSIFIED DRUG;

ATAXIA; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; HYPOACTIVITY; NEGATIVE SYNDROME; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE;

EID: 84907976534     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20140918102748     Document Type: Editorial

References (51)

1. Haro JM, Salvador-Carulla L. The SOHO (schizophrenia outpatient health outcome) study: Implications for the treatment of schizophrenia. CNS Drugs 2006;20(4):293-301. [CrossRef]
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association. Arlington, VA: American Psychiatric Publishing; 2013.p.99.
3. Katschnigm H. Schizophrenia and quality of life. Acta Psychiatr Scand 2000;407(suppl):S33-S37. [CrossRef]
4. Orsel S, Akdemir A, Dag I. The sensitivity of quality-of- life scale WHOQOL-100 to psychopathological measures in schizophrenia. Compr Psychiatry 2004;45(1):57-61. [CrossRef]
5. Barnes TR. Schizophrenia consensus group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25(5):567-620. [CrossRef]
6. Davis, M and Marder, S. Novel approaches for treating schizophrenia. Future Medicine 2012; pp. 40-48. (doi: 10.2217/ebo.12.31)
7. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148(11):1474-86.
8. Seeman P. All psychotic roads lead to increased dopamine D2High receptors: a perspective. Clin Schizophr Relat Psychoses 2008;1:351-5. [CrossRef]
9. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009;35(3):549-62. [CrossRef]
10. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 2003;1003:318-27. [CrossRef]
11. Krystal JH, Perry EB Jr., Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005;62(9):985-94. [CrossRef]
12. Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008;200(2):217-30. [CrossRef]
13. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148(10):1301-8.
14. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, et al. Translating glutamate from pathophysiology to treatment. Sci Transl Med 2011;3(102):102-2.
15. Veerman SRT, Schulte PFJ, Haan L de. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry 2014;47(4-5):121-30. [CrossRef]
16. Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005;30(11):1963-85. [CrossRef]
17. Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1). Curr Pharm Des 2013;19(7):1311-20.
18. Javitt DC. Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 2012;213:367-99. [CrossRef]
19. Yang CR, Svensson KA. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: The therapeutic potentials for schizophrenia. Pharmacol Ther 2008;120(3):317-32. [CrossRef]
20. Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-serine on persistent negative symptoms in schizophrenia: A retrospective analysis. Schizophr Res 2004;66(2-3):89-96. [CrossRef]
21. Nunes EA, Mackenzie EM, Rossolatos D, Perez-Parada J, Baker G, Dursun SM. D-serine and schizophrenia: an update. Expert Rev Neurother 2012;12(7):801-12. [CrossRef]
22. Shimazaki T, Kaku A, Chaki S. D-serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 2010;209(3):263-70. [CrossRef]
23. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-602. [CrossRef]
24. Lucarelli G, Ditonno P, Bettocchi C, Spilotros M, Rutigliano M, Vavallo A, et al. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncol 2013;9(6):899-907. [CrossRef]
25. Sreekumar A, Poisson LM, Rajendiran T, Khan AP, Cao P, Yu J, et al. Metabolic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457(7231):910-4. [CrossRef]
26. Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, et al. Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012;62(2):1152-61. [CrossRef]
27. Wolkenberg SE, Sur C. Recent progress in the discovery of non sarcosine based GlyT1 inhibitors. Curr Top Med Chem 2010;10(2):170-86. [CrossRef]
28. Borroni EI, Zhou Y, Ostrowitzki S, Alberati D, Kumar A, Hainzl D, et al. Pre-clinical characterization of [(11)C]Ro5013853 as a novel radiotracer for imaging of glycine transporter type 1 by positive emission tomography. Neuroimage 2013;75:291-300. doi: 10.1016/j.neuroimage.2011.11.090. Epub 2011 Dec 10. [CrossRef]
29. Martin-Facklam M, Pizzagalli F, Zhou Y, Ostrowitzki S, Raymont V, Brašić JR, et al. Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers. Neuropsychopharmacology 2013;38(3):504-12. [CrossRef]
30. Umbricht D, Alberat D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71(6):637-46. [CrossRef]
31. Bugarski-Kirola D, Wang A, Abi-Saab D, Blättler T. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. Eur Neuropsychopharmacol 2014;24(7):1024-36. [CrossRef]
32. Hoffmann-La Roche. A study of Ro4917838 (Bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia (WN25305). In: ClincialTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235559. NLM identifier: NCT01235559.
33. Hoffmann-La Roche. A study of Ro4917838 (Bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia (WN25306). In: ClincialTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235585. NLM identifier: NCT01235585.
34. Hoffmann-La Roche. A study of Ro4917838 (Bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia (NN25307). In: ClincialTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01235520. NLM identifier: NCT01235520.
35. Hoffmann-La Roche. A study of RO4917838 (Bitopertin) in Patients with persistent, predominant negative symptoms of schizophrenia (WN25309). In: ClincialTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192906. NLM identifier: NCT01192906.
36. Hoffmann-La Roche. A study of Ro4917838 (Bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia (WN25308). In: ClincialTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192880. NLM identifier: NCT01192880.
37. Hoffmann-La Roche. A study of Ro4917838 (Bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia (NN25310). In: ClincialTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01192867. NLM identifier: NCT01192867.
38. Carroll, J. Roche adds a slate of PhIII schizophrenia trial failures to bitopertin’s obituary. [Internet] April 15, 2014, Available from: http://www.fiercebiotech.com/story/roche-adds-slate-phiii-schizophrenia-trial-failures-bitopertins-obituary/2014-04-15.
39. Cetin M, Aricioglu F. Sights for sore eyes and disappointments in psychopharmacology. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014;24(2):111-114. [CrossRef]
40. Insel TR, Wang PS. Rethinking mental illness. JAMA 2014; 303(19):1970-71. Doi: 1001/jama.2010.555.
41. Gruber O, Santuccione AC, Aach H. Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry 2014;5(32):1-11.
42. Gunn RN, Murthy V, Catafau AM, Searle G, Bullich S, Slifstein M, et al. Translational characterization of [11C] GSK931145, a PET ligand for the glycine transporter type 1. Synapse 2011;65(12):1319-32. [CrossRef]
43. Chue P, Baker G. Glycine reuptake inhibition: A promising therapeutic strategy in the treatment of schizophrenia. Future Med Chem 2013 13:1475-7. [CrossRef]
44. Chue P, Lalonde JK. Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: Emerging pharmacological treatment options. Neuropsychiatr Dis Treat 2014;10:777-89. [CrossRef]
45. Goff CG. Bitopertin: The good news and bad news. JAMA Psychiatry 2014;71(6):621-2. [CrossRef]
46. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res 2014; 218(1-2):219-24. [CrossRef]
47. Grunder, G. Challenges for novel treatment approaches in schizophrenia. 29th CINP World Congress of Neuropsychopharmacology. Vancouver, B.C., Canada. June 22-26, 2014.
48. Umbricht, D. Clinical results of novel glutamatergic treatments. 29th CINP World Congress of Neuropsychopharmacology. Vancouver, B.C., Canada. June 22-26, 2014.
49. Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013;70(7):668-76. [CrossRef]
50. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013;70(12):1267-75. [CrossRef]
51. Gil-Ad I, Portnoy M, Tarasenko I, Bidder M, Kramer M, Taler M, et al. A novel analog of olanzapine linked to sarcosinyl moiety (pgw5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. Eur Neuropsychopharmacol 2014;24(3):425-36. [CrossRef]